JAMA Oncology Archive — Page 1 of 2

Authors on the study included, from left, Jennifer Pietenpol, PhD, Melinda Sanders, MD, Brian Lehmann, PhD, Vandana Abramson, MD, and Yu Shyr, PhD. (photo by Donn Jones)
December 15, 2023

Clinical trial shows efficacy for atezolizumab combined with carboplatin

Illustration of intertwined DNA double helices against a glowing blue and purple background.
November 17, 2022

Surgery for hereditary breast cancer

Similar rates of bilateral mastectomy in women with inherited mutations in high- and moderate-penetrance genes raises concerns about possible overtreatment of some patients, Vanderbilt researchers report.

Portrait of a smiling woman with long brown hair and glasses, wearing a patterned sweater and jeweled necklace, in a laboratory or office setting.
November 11, 2022

Study finds inherited link to appendix cancer

A Vanderbilt study is the first to show inherited risk factors for appendiceal cancer.

Studies by Andrew Glazer, PhD, Giovanni Davogustto, MD, and colleagues found that genetic testing with information from electronic health records can reveal undiagnosed heart rhythm disorders.
April 28, 2022

Studies combine genetic testing, electronic health records to find undiagnosed diseases

Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations.

Older couple indoors, with a woman in a yellow top looking concerned as a man in a pink shirt sits with his hands clasped near his mouth.
December 9, 2021

Prostate cancer treatment regret

Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.

VUMC NEWS logo in white lettering inside a cyan and yellow outlined square on a blue gradient background.
April 15, 2021

Method proposed to correct misinterpretations of long-term survival rates for immunotherapies

Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.